Antibodies

01 May 2020 Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)
30 Apr 2020 Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19
29 Apr 2020 RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II Clinical Trial in Urothelial Cancer
29 Apr 2020 Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR
29 Apr 2020 Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
29 Apr 2020 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
28 Apr 2020 First patient dosed in avdoralimab Phase II clinical trial in COVID-19 patients with severe pneumonia
28 Apr 2020 Immutep Reports Positive Phase II TACTI-002 Data
28 Apr 2020 New 6-year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis
28 Apr 2020 MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China
28 Apr 2020 Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia
28 Apr 2020 Novel anti-PD-1 drug was approved for melanoma treatment
27 Apr 2020 Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
27 Apr 2020 Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Polyclonal Immunoglobulin Product
27 Apr 2020 Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
27 Apr 2020 First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
27 Apr 2020 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
27 Apr 2020 MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
27 Apr 2020 Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
27 Apr 2020 Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
27 Apr 2020 Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR
25 Apr 2020 Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
24 Apr 2020 Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
24 Apr 2020 GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
23 Apr 2020 Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top